US009408826B2

(12) **United States Patent**
Iadonato et al.

(10) **Patent No.: US 9,408,826 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **ISOFLAVONE ANTI-VIRAL COMPOUNDS**

(75) Inventors: **Shawn P. Iadonato**, Seattle, WA (US); **Kristin Bedard**, Bellevue, WA (US)

(73) Assignee: **Kineta, Inc.**, Seattle, WA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1134 days.

(21) Appl. No.: **13/091,983**

(22) Filed: **Apr. 21, 2011**

(65) **Prior Publication Data**

US 2011/0262482 A1 Oct. 27, 2011

Related U.S. Application Data

(60) Provisional application No. 61/327,579, filed on Apr. 23, 2010.

(51) **Int. Cl.**

A61K 31/35	(2006.01)
C07D 311/00	(2006.01)
A61K 31/353	(2006.01)
A61K 31/4433	(2006.01)
C07D 311/36	(2006.01)
C07D 405/04	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/353*** (2013.01); ***A61K 31/4433*** (2013.01); ***C07D 311/36*** (2013.01); ***C07D 405/04*** (2013.01); *C12N 2770/24211* (2013.01); *C12N 2770/32211* (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/352; C07D 311/36
USPC 514/456; 549/403
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,618,998	B2	11/2009	Tzeng et al.	
7,880,059	B2	2/2011	Dixon et al.	
2005/0256124	A1	11/2005	Goodfellow et al.	
2007/0123566	A1	5/2007	Xu	
2008/0114056	A1 *	5/2008	Ritchie	C07D 311/36 514/456
2008/0138818	A1	6/2008	Tovey et al.	
2010/0009970	A1	1/2010	Johansen et al.	
2013/0039887	A1	2/2013	Iadonato et al.	

FOREIGN PATENT DOCUMENTS

CN	101301287		11/2008
JP	H0267218		3/1990
WO	WO99/49862	*	10/1999
WO	WO2004111027		12/2004
WO	WO2012003030	A2	1/2005
WO	WO 2006/002422	*	1/2006
WO	WO2006034219		3/2006
WO	WO 2008/0033449	*	3/2008
WO	WO2008080091		7/2008
WO	WO2009018338		2/2009
WO	2009-052411		4/2009

(Continued)

OTHER PUBLICATIONS

STN registration file, RN 610753-87-2, 2003.*

(Continued)

Primary Examiner — Shengjun Wang

(57) **ABSTRACT**

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

2 Claims, 3 Drawing Sheets